CURE Pharmaceutical Reports Increase in Revenue to $7.7 Million on a Pro Forma Basis in 2020

by Ryan Shatto | Apr 1, 2021 | Press Releases

Fiscal Year 2020 Highlights: Generated dramatic growth in total and pro forma revenue Released positive clinical data on its patented drug delivery technology and received new certifications at its research facility Acquired and expanded consumer wellness subsidiary...

CURE Pharmaceutical Launches Psychedelic Oral Film Program Targeting the Treatment of Mental Health Disorders

by Ryan Shatto | Mar 16, 2021 | Press Releases

OXNARD, Calif. – CURE Pharmaceutical Holding Corp. (“CURE” or the “Company”) (OTC: CURR), a vertically integrated drug delivery and product development company, announced today that it has launched a new initiative for the clinical...

CURE Pharmaceutical Announces Addition of Two New Clinical Development Programs Targeting Anti-Seizure and Antiviral Applications

by Ryan Shatto | Mar 10, 2021 | Press Releases

OXNARD, Calif. – CURE Pharmaceutical Holding Corp. (“CURE” or the “Company”) (OTC: CURR), a vertically integrated drug delivery and product development company, announced today that it has launched two new clinical development programs...

CURE Pharmaceutical’s Subsidiary Sera Labs Launches National Television, Radio & Digital Advertising Campaign for Nutri-Strips Sleep A.S.A.P.

by Ryan Shatto | Mar 3, 2021 | Press Releases

Sleep A.S.A.P. provides proof of concept and monetization for CURE’s patented oral thin-film technology LOS ANGELES & OXNARD, Calif. – CURE Pharmaceutical Holding Corp. (“CURE” or the “Company”) (OTC: CURR), a technology...

CURE Pharmaceutical Announces the Initiation of Clinical Trials for Erectile Dysfunction Product CUREfilm Blue™

by Ryan Shatto | Feb 23, 2021 | Press Releases

OXNARD, Calif. – CURE Pharmaceutical Holding Corp. (“CURE” or the “Company”) (OTC: CURR), a technology focused, vertically integrated drug delivery and product development company in the pharmaceutical and health & wellness space,...